Different medications for seasonal allergic rhinitis in adults: A systematic review and meta-analysis

Table 1 PubMed search strategy

Search	Query	Results
#1	((((Fluticasone[title/abstract]) OR (Fluticasone Furoate[title/abstract])) OR (Azelastine Fluticasone[title/abstract])) OR (Fluticasone Propionate[title/abstract])) OR (MP29-02[title/abstract])	4558
#2	Allergic rhinitis[title/abstract]	22643
#3	#1 AND #2	476

Table 2 Basic information of included literature

Ref.	Year	Treatment	Follow-up	Number of participants
				Total	Active treatment	Placebo
Fokkens et al[13]	2007	Fluticasone furoate 110 μg (QD) and placebo	2 wk	285	141	144
Kaiser et al[14]	2007	Fluticasone furoate 110 μg (2 sprays/nostril QD) and placebo	2 wk	299	151	148
Martin et al[15]	2007	Fluticasone furoate 110 μg (2 sprays/nostril QD) and placebo	2 wk	255	127	128
Andrews et al[12]	2009	Fluticasone furoate 110 μg (QD) and placebo	2 wk	453	224	229
		Fluticasone furoate 110 μg (QD) and placebo	2 wk	625	312	313
Jacobs et al[16]	2009	Fluticasone furoate 110 μg (QD) and placebo	2 wk	302	152	150
Okubo et al[17]	2009	Fluticasone furoate 110 μg (QD) and placebo	2 wk	223	151	72
		Fluticasone propionate 200 μg (BID) and placebo	2 wk	223	148	75
Han et al[18]	2011	Fluticasone furoate 110 μg (QD) and placebo	2 wk	137	67	70
Given et al[19]	2010	Fluticasone furoate 110 μg (QD) and placebo	4 wk	315	160	155
Maspero et al[20]	2010	Fluticasone furoate 110 μg (QD) and placebo	2 wk	1141	570	571
van Bavel et al[21]	1994	Fluticasone propionate 200 μg (2 sprays/nostril QD) and placebo	2 wk	155	78	77
Bronsky et al[22]	1996	Fluticasone propionate 200 μg (2 sprays/nostril QD) and placebo	4 wk	232	117	115
Howland et al[23]	1996	Fluticasone propionate 200 μg (2 sprays/nostril QD) and placebo	2 wk	154	77	77
Alvarado-Valdés et al[24]	1997	Fluticasone propionate 200 μg (2 sprays/nostril QD) and placebo	2 wk	211	105	106
Stern et al[25]	1997	Fluticasone propionate 200 μg (QD) and placebo	4-6 wk	254	190	64
Dykewicz et al[26]	2003	Fluticasone propionate 200 μg (QD) and placebo	4 wk	241	122	119
Hampel et al[27]	2010	Azelastine-fluticasone 137 μg (1 spray/nostril BID) and placebo	2 wk	304	153	151
		Fluticasone propionate 200 μg (2 sprays/nostril QD) and placebo	2 wk	302	151	151
Carr et al[28]	2012	Fluticasone propionate 200 μg (2 sprays/nostril QD) and placebo	2 wk	1704	846	858
		Azelastine-fluticasone 137 μg (1 spray/nostril BID) and placebo	2 wk	1706	848	858
Ford et al[29]	2015	Fluticasone propionate 200 μg (2 sprays/nostril QD) and placebo	2 wk	341	170	171
Ratner et al[30]	2009	Fluticasone propionate 200 μg (2 sprays/nostril QD) and azelastine-fluticasone 137 μg (1 spray/nostril BID)	2 wk	102	50	52
Ratner et al[31]	2015	Fluticasone propionate 200 μg (2 sprays/nostril QD) and placebo	2 wk	626	314	312

Table 3 League table of different treatment methods, mean difference (95%CI)¹

	Relative total nasal symptom score
Relative total ocular symptom score	Placebo	-1.43 (-1.78 to -1.08)	-1.36 (-1.70 to -1.02)	-2.28 (-2.95 to -1.60)
	1.00 (0.66-1.34)	Fluticasone propionate	0.07 (-0.40-0.54)	-0.84 (-1.51 to -0.18)
	0.63 (0.47-0.79)	-0.37 (-0.75-0.00)	Fluticasone furoate	-0.91 (-1.66 to -0.17)
	1.40 (1.04-1.76)	0.53 (0.14-0.92)	0.77 (0.38-1.16)	Azelastine-fluticasone

¹The results below each treatment method column are the relative total ocular symptom score comparison results between the modified treatment method and the baseline treatment method; the results above each treatment method column are the relative total nasal symptom score comparison results between the modified treatment method and the baseline treatment method.